Roche has no plans to sell its diabetes testing business, despite a pummeling in the past three years from U.S. price cuts, and the Swiss drugmaker expects the unit to return to sales growth in 2017.
Roland Diggelmann, head of Roche diagnostics, said the fundamentals for blood glucose meters remained strong given the growing incidence of type 2 diabetes, which is linked to obesity, especially in emerging markets.
"You shouldn't expect growth this year, but next year I think it will go back to growth. That's definitely our vision," he told Reuters during a visit to London.
Roland Diggelmann, head of Roche diagnostics, said the fundamentals for blood glucose meters remained strong given the growing incidence of type 2 diabetes, which is linked to obesity, especially in emerging markets.
"You shouldn't expect growth this year, but next year I think it will go back to growth. That's definitely our vision," he told Reuters during a visit to London.
